Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Evoke Pharma (EVOK) Accounts Payables (2020 - 2025)

Historic Accounts Payables for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to $3.9 million.

  • Evoke Pharma's Accounts Payables rose 7897.63% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 7897.63%. This contributed to the annual value of $2.3 million for FY2024, which is 3676.95% up from last year.
  • Per Evoke Pharma's latest filing, its Accounts Payables stood at $3.9 million for Q3 2025, which was up 7897.63% from $3.6 million recorded in Q2 2025.
  • Evoke Pharma's 5-year Accounts Payables high stood at $3.9 million for Q3 2025, and its period low was $519001.0 during Q2 2021.
  • For the 5-year period, Evoke Pharma's Accounts Payables averaged around $1.6 million, with its median value being $1.4 million (2023).
  • Per our database at Business Quant, Evoke Pharma's Accounts Payables tumbled by 3137.19% in 2021 and then skyrocketed by 9239.14% in 2022.
  • Evoke Pharma's Accounts Payables (Quarter) stood at $874028.0 in 2021, then grew by 6.9% to $934312.0 in 2022, then surged by 83.21% to $1.7 million in 2023, then soared by 36.77% to $2.3 million in 2024, then surged by 67.28% to $3.9 million in 2025.
  • Its last three reported values are $3.9 million in Q3 2025, $3.6 million for Q2 2025, and $2.8 million during Q1 2025.